Two Sigma Advisers LP Grows Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Two Sigma Advisers LP increased its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 57.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,630,600 shares of the company's stock after purchasing an additional 596,100 shares during the quarter. Two Sigma Advisers LP owned 0.14% of Teva Pharmaceutical Industries worth $35,938,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Diversify Advisory Services LLC raised its position in shares of Teva Pharmaceutical Industries by 2.5% in the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock valued at $426,000 after buying an additional 496 shares during the last quarter. Thrivent Financial for Lutherans grew its position in shares of Teva Pharmaceutical Industries by 0.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock worth $4,964,000 after acquiring an additional 699 shares during the last quarter. Townsquare Capital LLC lifted its holdings in Teva Pharmaceutical Industries by 2.1% in the fourth quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock worth $885,000 after purchasing an additional 812 shares during the period. Metis Global Partners LLC grew its holdings in Teva Pharmaceutical Industries by 6.7% during the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock worth $302,000 after acquiring an additional 860 shares during the period. Finally, Quadrant Capital Group LLC boosted its stake in shares of Teva Pharmaceutical Industries by 27.7% during the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock worth $96,000 after acquiring an additional 949 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Trading Up 0.0%

Shares of NYSE TEVA traded up $0.01 during mid-day trading on Friday, hitting $16.95. The stock had a trading volume of 6,476,349 shares, compared to its average volume of 9,978,853. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a 1 year low of $12.47 and a 1 year high of $22.80. The firm has a market cap of $19.21 billion, a P/E ratio of -11.69, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The business has a 50 day moving average price of $15.38 and a two-hundred day moving average price of $17.37.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The business had revenue of $3.89 billion during the quarter, compared to analysts' expectations of $3.99 billion. During the same quarter in the previous year, the business earned $0.48 earnings per share. The firm's quarterly revenue was up 1.9% compared to the same quarter last year. On average, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analyst Ratings Changes

TEVA has been the topic of several recent research reports. Bank of America raised their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Barclays dropped their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. UBS Group lowered their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Finally, JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $24.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.